Vedanta Biosciences’ Key Microbiome Patents Fully Upheld in Three European Opposition Proceedings
Vedanta Biosciences , a clinical-stage company developing a potential new category of oral therapies based on defined bacterial consortia, today announced that the Opposition Division of the European Patent Office (EPO) has fully upheld Vedanta’s foundational patents EP3178483B1, EP3552613B1, and EP3539548B1 (the “Honda patents”) in oral opposition proceedings held in Munich over the course of three weeks.
- Vedanta Biosciences , a clinical-stage company developing a potential new category of oral therapies based on defined bacterial consortia, today announced that the Opposition Division of the European Patent Office (EPO) has fully upheld Vedanta’s foundational patents EP3178483B1, EP3552613B1, and EP3539548B1 (the “Honda patents”) in oral opposition proceedings held in Munich over the course of three weeks.
- In all three cases, the originally granted claims of the patents were upheld without any modification and were deemed valid and supported by the EPO.
- The Honda patents are based on groundbreaking work at the lab of Dr. Kenya Honda, a scientific co-founder of Vedanta, which identified clostridial bacteria that induce significant immune responses.
- The Honda patents, together with additional Vedanta patents, provide the company with a leading IP position in the microbiome field.